Buy These Stocks Before Nov 3rd

There's a major catalyst for biotech stocks kicking off soon... [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here. Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, In just a few days, Obesity Week 2024 will kick off in San Antonio, Texas. In fact, the “preeminent international conference for obesity researchers and clinicians, ObesityWeek is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy,” says The Obesity Society. It's also where some of the top obesity companies will present their latest data. --------------------------------------------------------------- Company: Viking Therapeutics (SYM: VKTX) Look at Viking Therapeutics (SYM: VKTX), for example. The company is set to provide results from its Phase 2 VENTURE clinical trial with its subcutaneous formulation of VK2735. It’s other presentation will highlight results from its Phase 1 multiple ascending dose clinical trial of its oral formulation of VK2735. --------------------------------------------------------------- The Opportunistic Trader [Will it be Trump or Harris?]( Market legend with an uncanny track record predicts total chaos either way with an urgent message for anyone at or near retirement. In an exclusive interview on Wednesday, October 30, at 8 p.m. ET, he’ll explain everything and reveal a free ticker for the coming chaos. [Click to instantly add your email to the guest list now.]( When you click the link, your email will automatically be added to the guest list. --------------------------------------------------------------- Company: Fractyl Health (SYM: GUTS) Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), announced that it will present weight maintenance data from both its Revita and Rejuva platforms at the meeting, too. The company also notes that, “A pivotal study of Revita in weight maintenance for patients with obesity after discontinuation of GLP-1-based drugs, called REMAIN-1, is underway with anticipated data readouts from the open-label study in weight maintenance in the fourth quarter of 2024 and an anticipated mid-point analysis of the REMAIN-1 in the second quarter of 2025. A pivotal study of Revita in patients with T2D who are inadequately controlled on any glucose lowering agent, REVITALIZE-1, is currently enrolling in the United States and Europe.” --------------------------------------------------------------- InvestorPlace [Buffett, Bloomberg, & 48 Congress Members Are Buying ONE Sector]( [gurus]( Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… The last time we saw the world's wealthiest investors move their cash into this corner of the market, Stocks exploded 2,020%, 5,609% Even as high as 8,437% in just ONE year. Now, it's all happening again.[Click here for the details.]( --------------------------------------------------------------- Company: Rhythm Pharmaceuticals (SYM: RYTM) Rhythm Pharmaceuticals is also set to report its third quarter 2024 financial results and provide a corporate update at the meeting. It will also deliver five poster presentations on Weight Loss at 18 Months of Setmelanotide in 2- to 6-Year-Old Patients with Rare MC4R Pathway Diseases; Body Composition Improvements After 12 Months of Setmelanotide in Acquired Hypothalamic Obesity; Risk Factors Correlating with MC4R Pathway Variants on Genetic Testing; DAYBREAK Trial: Setmelanotide vs Placebo in Patients with Melanocortin-4 Receptor Pathway Variants; and 3-Month Real-World Setmelanotide Hunger and Weight Outcomes in Patients with Hypothalamic Obesity. --------------------------------------------------------------- Mode Mobile [The World's Most Accessible Income-Generating Asset: 7 Billion Consumers]( clock in a staggering 40 hours a week on smartphones; this number is even greater for younger generations. Taking a cue from Uber and Airbnb, Mode monetizes phone usage to unlock a new asset class, akin to how cars and homes were turned into income generators. And Mode’s market is up to 10X bigger than Uber’s. Mode has already helped users earn and save $325M+ and is already being sold by Amazon, Walmart, and BestBuy, and more. [🚨Claim your exclusive share bonus by investing in Mode today. Join 25,000+ investors & get up to 100% bonus shares today.]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own shares of any "weight-loss" biotech stocks? Are there any other under-the-radar biotechs you've got your eye on? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that this is a paid advertisement for Mode Mobile Reg A offering and we have received or expect to receive compensation in connection with the disbursing this communication for Mode Mobile . The compensation consists of up to $5,000 and was received/will be received from Mode Mobile. This compensation should not be considered as an endorsement of the securities of Mode Mobile and we are not responsible for any errors or omissions in any information provided about the securities of Mode Mobile. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 10/30/24 [Behind the Markets]( [Unsubscribe](